Memphasys
ASX:MEMSydney, Australia· Est.
Australian‑based MedTech firm delivering electrophoretic sperm‑separation and oxidative‑stress diagnostics for human and animal fertility markets.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Australian‑based MedTech firm delivering electrophoretic sperm‑separation and oxidative‑stress diagnostics for human and animal fertility markets.
Reproductive HealthFertility
Technology Platform
Proprietary electrophoretic membrane technology for sperm separation (Felix™) and oxidative‑stress measurement (RoXsta™).
Opportunities
Regulatory clearances in the EU, Australia and China will open large, high‑margin markets; expanding diagnostic RoXsta™ and animal‑reproduction products can diversify revenue streams.
Risk Factors
Delays in multi‑regional regulatory approvals and adoption hurdles against entrenched IVF device manufacturers could constrain growth.
Competitive Landscape
Key competitors include CooperSurgical, Vitrolife and Origio; Memphasys differentiates through electrophoretic sperm selection and integrated oxidative‑stress diagnostics, offering higher precision and potentially better IVF outcomes.